Prior to investing into a fund, please read the relevant key information document which contains important information about the fund. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. This website does not contain any personal recommendations for a particular course of action, service or product. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. All rights reserved.Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. Benzinga does not provide investment advice. Read More: Investor Sentiment Declines Slightly Following Inflation Data BIO Price Action: Shares of Bio-Rad Laboratories fell 0.3% to close at $365.69 on Wednesday.The company has a 52-week low of $344.63. "The expected decline in first quarter COVID-related sales resulted in lower year-over-year total revenues however, we are encouraged by continued underlying strength of our core business in Life Science and Clinical Diagnostics," said Norman Schwartz, Bio-Rad’s President and Chief Executive Officer. Bio-Rad Laboratories reported worse-than-expected Q1 financial results.SHC Price Action: Shares of Sotera Health fell 0.3% to close at $14.66 on Wednesday.“As we outlined in our fourth-quarter 2022 earnings call, our first-quarter total revenue was below the same quarter last year, driven by the anticipated timing of Nordion Cobalt-60 harvest schedules and lower volumes for the Nelson Labs and Sterigenics businesses, which is typical for the first quarter of the year,” said Chairman and Chief Executive Officer, Michael B. Sotera Health posted downbeat quarterly results.SGMO Price Action: Shares of Sangamo Therapeutics fell 0.8% to close at $1.27 on Wednesday.The company’s stock has a 52-week low of $1.18. Our Phase 1/2 Fabry study continues to enroll and dose patients, alongside preparations for a potential Phase 3 trial expected to commence by the end of 2023,” said Sandy Macrae, Chief Executive Officer of Sangamo. “This quarter, Sangamo continued to advance its clinical and pre-clinical pipeline. Sangamo Therapeutics said it sees Q1 revenue of $158 million.ACCD Price Action: Shares of Accolade fell 0.8% to close at $10.93 on Wednesday.The company’s stock has a 52-week low of $5.07. “Fiscal year 2023 marked a transformational time for Accolade, as we tightly integrated our acquisitions, greatly expanded our presence across the healthcare ecosystem, and delivered against our financial objectives,” said Rajeev Singh, Accolade Chief Executive Officer. BIO RAD LABORATORIES INC Industry Group Code: 339113 Ranks within this company's. Accolade reported worse-than-expected Q4 sales results. Norman Schwartz - Chairman, CEO & President Simon May - EVP & President, Life Science Group Conference Call Participants Brandon Couillard - Jefferies Patrick Donnelly - Citigroup Daniel.DGX Price Action: Shares of Quest Diagnostics fell 0.9% to close at $132.43 on Wednesday.The company’s stock has a 52-week low of $120.40. Quest Diagnostics posted Q1 FY23 adjusted EPS of $2.04, down 36.6% Y/Y, beating the consensus of $1.97.Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. An asset is typically considered oversold when the RSI is below 30. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. Since we first began 70 years ago, Bio-Rad has been committed to its vision of providing useful products and solutions that help life science researchers accelerate the discovery process and clinical diagnostics laboratorians obtain faster, more accurate results.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |